BioCryst Pharmaceuticals, Inc.
8.115USD
-0.6900 (-7.84%)
Fetching financial statements from SEC filings…
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 218 | 156 | 407 | 159 | 163 | 146 | 132 | 117 |
| Cost of Revenue | 4 | 5 | 10 | 2 | 3 | 5 | 6 | 3 |
| Gross Profit | 214 | 151 | 397 | 157 | 161 | 141 | 125 | 114 |
| Operating Income | 98 | -702 | 260 | 30 | 30 | 21 | -5 | 8 |
| Net Income | 78 | -722 | 246 | 13 | 5 | 0 | -27 | -14 |
| EPS (Diluted) | $0.30 | $-2.98 | $1.13 | $0.06 | $0.02 | $0.00 | $-0.13 | $-0.07 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)